vs
AMES NATIONAL CORP（ATLO）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是AMES NATIONAL CORP的1.6倍（$30.3M vs $18.7M），AMES NATIONAL CORP净利率更高（34.9% vs -221.3%，领先256.2%），REGENXBIO Inc.同比增速更快（43.0% vs 26.7%），AMES NATIONAL CORP自由现金流更多（$20.7M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 19.5%）
艾姆斯国家公司是总部位于美国爱荷华州的金融控股企业，运营多家社区银行子公司，提供零售及商业银行全品类服务，涵盖存取款、个人及企业贷款、抵押贷款、财富管理等，主要服务爱荷华州中部的消费者和中小微企业。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ATLO vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.6倍
$18.7M
营收增速更快
RGNX
高出16.4%
26.7%
净利率更高
ATLO
高出256.2%
-221.3%
自由现金流更多
ATLO
多$73.5M
$-52.8M
两年增速更快
RGNX
近两年复合增速
19.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $30.3M |
| 净利润 | $6.5M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 44.3% | -190.0% |
| 净利率 | 34.9% | -221.3% |
| 营收同比 | 26.7% | 43.0% |
| 净利润同比 | 85.4% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATLORGNX
| Q4 25 | $18.7M | $30.3M | ||
| Q3 25 | $16.6M | $29.7M | ||
| Q2 25 | $16.1M | $21.4M | ||
| Q1 25 | $15.5M | $89.0M | ||
| Q4 24 | $14.7M | $21.2M | ||
| Q3 24 | $13.5M | $24.2M | ||
| Q2 24 | $13.5M | $22.3M | ||
| Q1 24 | $13.1M | $15.6M |
净利润ATLORGNX
| Q4 25 | $6.5M | $-67.1M | ||
| Q3 25 | $4.6M | $-61.9M | ||
| Q2 25 | $4.5M | $-70.9M | ||
| Q1 25 | $3.4M | $6.1M | ||
| Q4 24 | $3.5M | $-51.2M | ||
| Q3 24 | $2.2M | $-59.6M | ||
| Q2 24 | $2.2M | $-53.0M | ||
| Q1 24 | $2.3M | $-63.3M |
毛利率ATLORGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率ATLORGNX
| Q4 25 | 44.3% | -190.0% | ||
| Q3 25 | 34.5% | -176.3% | ||
| Q2 25 | 35.0% | -296.3% | ||
| Q1 25 | 27.4% | 13.6% | ||
| Q4 24 | 29.4% | -242.1% | ||
| Q3 24 | 19.4% | -256.6% | ||
| Q2 24 | 19.0% | -251.3% | ||
| Q1 24 | 20.8% | -408.8% |
净利率ATLORGNX
| Q4 25 | 34.9% | -221.3% | ||
| Q3 25 | 27.5% | -208.3% | ||
| Q2 25 | 28.0% | -331.8% | ||
| Q1 25 | 22.3% | 6.8% | ||
| Q4 24 | 23.8% | -241.3% | ||
| Q3 24 | 16.4% | -246.3% | ||
| Q2 24 | 16.2% | -237.7% | ||
| Q1 24 | 17.6% | -405.4% |
每股收益（稀释后）ATLORGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $126.8M | $230.1M |
| 总债务越低越好 | $18.4M | — |
| 股东权益账面价值 | $207.9M | $102.7M |
| 总资产 | $2.1B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.09× | — |
8季度趋势，按日历期对齐
现金及短期投资ATLORGNX
| Q4 25 | $126.8M | $230.1M | ||
| Q3 25 | $108.2M | $274.2M | ||
| Q2 25 | $95.2M | $323.3M | ||
| Q1 25 | $163.4M | $267.9M | ||
| Q4 24 | $101.2M | $234.7M | ||
| Q3 24 | $59.0M | $255.5M | ||
| Q2 24 | $63.4M | $290.4M | ||
| Q1 24 | $111.4M | $338.7M |
总债务ATLORGNX
| Q4 25 | $18.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $20.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ATLORGNX
| Q4 25 | $207.9M | $102.7M | ||
| Q3 25 | $200.6M | $161.5M | ||
| Q2 25 | $193.0M | $213.7M | ||
| Q1 25 | $183.1M | $274.2M | ||
| Q4 24 | $174.7M | $259.7M | ||
| Q3 24 | $183.4M | $301.4M | ||
| Q2 24 | $167.1M | $348.3M | ||
| Q1 24 | $165.5M | $390.7M |
总资产ATLORGNX
| Q4 25 | $2.1B | $453.0M | ||
| Q3 25 | $2.1B | $525.2M | ||
| Q2 25 | $2.1B | $581.0M | ||
| Q1 25 | $2.2B | $490.9M | ||
| Q4 24 | $2.1B | $466.0M | ||
| Q3 24 | $2.1B | $519.1M | ||
| Q2 24 | $2.1B | $569.4M | ||
| Q1 24 | $2.2B | $629.2M |
负债/权益比ATLORGNX
| Q4 25 | 0.09× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.11× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $20.7M | $-52.8M |
| 自由现金流率自由现金流/营收 | 110.8% | -174.0% |
| 资本支出强度资本支出/营收 | 3.4% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.28× | — |
| 过去12个月自由现金流最近4个季度 | $34.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ATLORGNX
| Q4 25 | $21.3M | $-52.3M | ||
| Q3 25 | $2.8M | $-56.0M | ||
| Q2 25 | $4.0M | $-49.3M | ||
| Q1 25 | $7.1M | $33.6M | ||
| Q4 24 | $14.3M | $-31.6M | ||
| Q3 24 | $3.1M | $-40.5M | ||
| Q2 24 | $3.9M | $-45.5M | ||
| Q1 24 | $1.4M | $-55.5M |
自由现金流ATLORGNX
| Q4 25 | $20.7M | $-52.8M | ||
| Q3 25 | $2.6M | $-56.5M | ||
| Q2 25 | $3.9M | $-49.7M | ||
| Q1 25 | $6.9M | $32.6M | ||
| Q4 24 | $14.0M | $-32.7M | ||
| Q3 24 | $3.0M | $-40.9M | ||
| Q2 24 | $3.8M | $-46.0M | ||
| Q1 24 | $1.3M | $-56.0M |
自由现金流率ATLORGNX
| Q4 25 | 110.8% | -174.0% | ||
| Q3 25 | 16.0% | -189.9% | ||
| Q2 25 | 24.2% | -232.8% | ||
| Q1 25 | 44.8% | 36.6% | ||
| Q4 24 | 94.9% | -154.2% | ||
| Q3 24 | 22.5% | -168.9% | ||
| Q2 24 | 28.1% | -206.2% | ||
| Q1 24 | 10.0% | -358.5% |
资本支出强度ATLORGNX
| Q4 25 | 3.4% | 1.7% | ||
| Q3 25 | 0.6% | 1.7% | ||
| Q2 25 | 0.7% | 1.8% | ||
| Q1 25 | 1.3% | 1.2% | ||
| Q4 24 | 2.0% | 5.1% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 0.7% | 2.1% | ||
| Q1 24 | 0.5% | 3.6% |
现金转化率ATLORGNX
| Q4 25 | 3.28× | — | ||
| Q3 25 | 0.60× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 2.07× | 5.53× | ||
| Q4 24 | 4.07× | — | ||
| Q3 24 | 1.40× | — | ||
| Q2 24 | 1.78× | — | ||
| Q1 24 | 0.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATLO
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
